193 related articles for article (PubMed ID: 35870421)
1. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Diaby V; Alqhtani H; van Boemmel-Wegmann S; Wang CY; Ali AA; Balkrishnan R; Ko Y; Palacio S; de Lima Lopes G
Breast; 2020 Feb; 49():141-148. PubMed ID: 31805500
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Leung HWC; Chan ALF; Muo CH; Leung JH
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer.
Lai SP; Wang SY; Chan AL; Leung JH; Yip HT
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):541-549. PubMed ID: 38372034
[TBL] [Abstract][Full Text] [Related]
13. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
Lang HC; Chen HW; Chiou TJ; Chan AL
J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China.
Wang H; Wang Y; Gong R; Geng Y; Li L
Ann Palliat Med; 2021 Nov; 10(11):11382-11393. PubMed ID: 34872264
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
[TBL] [Abstract][Full Text] [Related]
20. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]